As part of its advocacy program in Europe, ACRO submits regulatory comments to European officials. This comment letter, submitted by ACRO to European Commission in 2016 about Definition of Investigational Medicinal Products (IMPs) and use of Auxiliary Medicinal Products (AMPs) can be found below.